{"id":14099,"date":"2026-01-31T06:00:00","date_gmt":"2026-01-31T11:00:00","guid":{"rendered":"https:\/\/cov19longhaulfoundation.org\/?p=14099"},"modified":"2025-11-25T18:45:39","modified_gmt":"2025-11-25T23:45:39","slug":"etiology-of-long-covid-skin-conditions","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=14099","title":{"rendered":"Etiology of Long COVID Skin Conditions"},"content":{"rendered":"\n<p class=\"has-small-font-size wp-block-paragraph\">John Murphy, CEO, The COVID-19 Long-haul Foundation<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Introduction<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The COVID\u201119 pandemic has left an indelible mark not only on global health systems but also on the human body in ways that continue to unfold. Among the myriad sequelae of SARS\u2011CoV\u20112 infection, dermatological manifestations occupy a unique space: they are visible, often distressing, and serve as windows into systemic pathology. Long COVID \u2014 defined as persistent or relapsing symptoms beyond 12 weeks of acute infection \u2014 has been recognized as a multisystem disorder encompassing respiratory, neurological, cardiovascular, and immunological domains. Yet the skin, our most accessible organ, provides critical clues to the underlying mechanisms of chronic disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cutaneous signs such as \u201cCOVID toes,\u201d urticaria, papulosquamous eruptions, telogen effluvium, and retiform purpura have been documented across continents. These manifestations are not merely cosmetic; they reflect vascular injury, immune dysregulation, and genomic predispositions that mirror systemic involvement. Understanding their etiology is therefore essential to unraveling the broader pathophysiology of long COVID.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Etiology<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">1. Viral Persistence<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Evidence suggests that SARS\u2011CoV\u20112 may persist in cutaneous tissues long after acute infection. Viral RNA and spike protein have been detected in endothelial cells and keratinocytes weeks after recovery. This persistence may drive chronic inflammation, leading to chilblain\u2011like lesions and vasculitic rashes.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">2. Immune Dysregulation<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Long COVID is characterized by sustained immune activation.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cytokine storm residues<\/strong>: Elevated IL\u20116, TNF\u2011\u03b1, and interferon\u2011\u03b3 persist in some patients, fueling urticaria and papulosquamous eruptions.<\/li>\n\n\n\n<li><strong>Mast cell activation<\/strong>: Dysregulated mast cells release histamine and tryptase, contributing to chronic hives and angioedema.<\/li>\n\n\n\n<li><strong>Autoimmunity<\/strong>: Molecular mimicry between viral antigens and host proteins may trigger autoimmune skin diseases such as lupus\u2011like rashes.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">3. Microvascular Injury<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The skin is highly vascularized, making it susceptible to endothelial damage.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Thrombotic microangiopathy<\/strong>: SARS\u2011CoV\u20112 induces platelet activation and complement deposition, resulting in retiform purpura and livedo reticularis.<\/li>\n\n\n\n<li><strong>Hypoxia<\/strong>: Microthrombi impair oxygen delivery, producing acral cyanosis and chilblains.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">4. Genomic Susceptibility<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Genetic polymorphisms influence cutaneous outcomes.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ACE2 and TMPRSS2 variants<\/strong>: Altered expression in keratinocytes may facilitate viral entry.<\/li>\n\n\n\n<li><strong>HLA alleles<\/strong>: Certain haplotypes correlate with heightened risk of autoimmune rashes.<\/li>\n\n\n\n<li><strong>Cytokine gene polymorphisms<\/strong>: Variants in IL\u20116 and TNF\u2011\u03b1 genes predispose to exaggerated inflammatory responses.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">5. Stress and Neuroimmune Pathways<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Psychological stress during the pandemic exacerbates dermatological conditions.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neuroimmune signaling<\/strong>: Stress hormones such as cortisol modulate mast cell activity, worsening urticaria and eczema.<\/li>\n\n\n\n<li><strong>Hair cycle disruption<\/strong>: Systemic stress precipitates telogen effluvium, leading to diffuse hair shedding.<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading has-medium-font-size\"><strong>Genomics and Pathology of Long COVID Skin Conditions<\/strong><\/h1>\n\n\n\n<h3 class=\"wp-block-heading\">Genomics<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">1. ACE2 and TMPRSS2 Expression in Skin<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">SARS\u2011CoV\u20112 gains entry into host cells via the ACE2 receptor, facilitated by TMPRSS2 protease.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Keratinocytes and endothelial cells<\/strong> in the skin express ACE2, albeit at lower levels than respiratory epithelium.<\/li>\n\n\n\n<li>Variants in ACE2 and TMPRSS2 genes may alter susceptibility to viral persistence in cutaneous tissues.<\/li>\n\n\n\n<li>Studies using single\u2011cell RNA sequencing have confirmed ACE2 expression in basal keratinocytes, suggesting a genomic basis for direct viral involvement in skin lesions.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">2. HLA Associations<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Human leukocyte antigen (HLA) polymorphisms shape immune responses.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Certain alleles (e.g., HLA\u2011B<em>15:01, HLA\u2011DRB1<\/em>03) have been linked to exaggerated cutaneous inflammation.<\/li>\n\n\n\n<li>These alleles predispose to autoimmune phenomena, including lupus\u2011like rashes and psoriasis exacerbations.<\/li>\n\n\n\n<li>Genomic mapping of long COVID cohorts reveals enrichment of autoimmunity\u2011associated haplotypes.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">3. Cytokine Gene Polymorphisms<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Variants in cytokine genes influence inflammatory cascades.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL\u20116 promoter polymorphisms<\/strong> correlate with higher serum IL\u20116 levels, driving urticaria and papulosquamous eruptions.<\/li>\n\n\n\n<li><strong>TNF\u2011\u03b1 polymorphisms<\/strong> enhance mast cell activation, worsening hives and angioedema.<\/li>\n\n\n\n<li><strong>Interferon pathway variants<\/strong> may explain persistence of chilblain\u2011like lesions in some patients.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">4. Epigenetic Regulation<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Beyond DNA sequence, epigenetic changes modulate skin responses.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>DNA methylation<\/strong> of cytokine promoters alters transcriptional activity.<\/li>\n\n\n\n<li><strong>Histone modifications<\/strong> in keratinocytes influence viral persistence.<\/li>\n\n\n\n<li>Stress\u2011induced epigenetic changes exacerbate telogen effluvium and eczema flares.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Pathology<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">1. Histopathology of COVID Toes<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Biopsies of chilblain\u2011like lesions reveal:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Endothelial swelling and necrosis<\/strong><\/li>\n\n\n\n<li><strong>Perivascular lymphocytic infiltrates<\/strong><\/li>\n\n\n\n<li><strong>Microthrombi in dermal vessels<\/strong><\/li>\n\n\n\n<li><strong>Complement deposition (C5b\u20119)<\/strong>, indicating immune complex\u2011mediated injury<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These findings mirror systemic microvascular pathology in severe COVID.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">2. Vasculitis and Thrombotic Microangiopathy<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Retiform purpura and livedo reticularis reflect vascular injury.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Histology<\/strong>: Fibrin thrombi occluding dermal vessels, neutrophilic infiltration, and leukocytoclasia.<\/li>\n\n\n\n<li><strong>Pathogenesis<\/strong>: Complement activation and platelet aggregation drive clot formation.<\/li>\n\n\n\n<li><strong>Clinical correlation<\/strong>: Associated with severe disease and hospitalization.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">3. Interface Dermatitis<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Papulosquamous eruptions often show:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Basal cell vacuolization<\/strong><\/li>\n\n\n\n<li><strong>Lymphocytic infiltration at dermo\u2011epidermal junction<\/strong><\/li>\n\n\n\n<li><strong>Hyperkeratosis and parakeratosis<\/strong> resembling psoriasis or pityriasis rosea. This suggests immune\u2011mediated keratinocyte injury.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">4. Urticaria and Mast Cell Activation<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Biopsies of chronic urticaria in long COVID reveal:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dermal edema<\/strong><\/li>\n\n\n\n<li><strong>Perivascular mast cell infiltration<\/strong><\/li>\n\n\n\n<li><strong>Degranulation with histamine release<\/strong> These findings confirm mast cell dysregulation as a driver of persistent hives.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">5. Hair Follicle Pathology<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Telogen effluvium reflects disruption of the hair cycle.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Histology<\/strong>: Increased telogen follicles, reduced anagen follicles.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Systemic stress, cytokine surge, and microvascular injury precipitate premature follicle transition.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Physiology<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">1. Cutaneous Vascular Physiology<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The skin is a highly vascular organ, with dermal capillaries supplying oxygen and nutrients to keratinocytes, fibroblasts, and hair follicles.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Microvascular injury<\/strong> in long COVID disrupts this balance, leading to hypoxia, ischemia, and inflammatory signaling.<\/li>\n\n\n\n<li><strong>Endothelial dysfunction<\/strong>: SARS\u2011CoV\u20112 infection induces endothelial apoptosis and loss of nitric oxide signaling, impairing vasodilation.<\/li>\n\n\n\n<li><strong>Complement activation<\/strong>: Deposition of C5b\u20119 complexes damages dermal vessels, producing purpura and livedo reticularis.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">2. Neuroimmune Signaling<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The skin is an immunological and neurological interface.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mast cells<\/strong> release histamine, tryptase, and cytokines, driving urticaria and angioedema.<\/li>\n\n\n\n<li><strong>Neuropeptides<\/strong> such as substance P and calcitonin gene\u2011related peptide (CGRP) amplify pruritus and vasodilation.<\/li>\n\n\n\n<li><strong>Stress hormones<\/strong> (cortisol, catecholamines) modulate mast cell activity, linking psychological stress to dermatological flares.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">3. Hair Cycle Physiology<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Hair follicles cycle through anagen (growth), catagen (regression), and telogen (rest).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Telogen effluvium<\/strong> occurs when systemic stress or cytokine surges prematurely shift follicles into telogen.<\/li>\n\n\n\n<li><strong>Cytokine involvement<\/strong>: IL\u20111 and TNF\u2011\u03b1 inhibit keratinocyte proliferation, accelerating follicle regression.<\/li>\n\n\n\n<li><strong>Microvascular compromise<\/strong>: Reduced blood flow impairs follicle nutrition, worsening hair shedding.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Clinical Manifestations<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">1. COVID Toes (Chilblains\/Pernio)<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Presentation<\/strong>: Painful, erythematous or violaceous lesions on toes and fingers, often with swelling.<\/li>\n\n\n\n<li><strong>Duration<\/strong>: Can persist for weeks to months in long COVID.<\/li>\n\n\n\n<li><strong>Pathophysiology<\/strong>: Interferon\u2011driven inflammation and microvascular injury.<\/li>\n\n\n\n<li><strong>Histology<\/strong>: Lymphocytic vasculitis, endothelial swelling, microthrombi.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">2. Urticaria and Angioedema<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Presentation<\/strong>: Migratory, pruritic wheals; sometimes accompanied by swelling of lips or eyelids.<\/li>\n\n\n\n<li><strong>Duration<\/strong>: Chronic urticaria lasting >6 weeks has been reported in long COVID.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Mast cell activation, histamine release, and autoantibody formation.<\/li>\n\n\n\n<li><strong>Impact<\/strong>: Significant impairment of quality of life due to itching and sleep disturbance.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">3. Papulosquamous Eruptions<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Presentation<\/strong>: Scaly papules and plaques resembling psoriasis or pityriasis rosea.<\/li>\n\n\n\n<li><strong>Duration<\/strong>: May last 20\u201370 days, sometimes recurring.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: T\u2011cell mediated keratinocyte injury, cytokine dysregulation.<\/li>\n\n\n\n<li><strong>Histology<\/strong>: Interface dermatitis, parakeratosis, basal cell vacuolization.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">4. Telogen Effluvium<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Presentation<\/strong>: Diffuse hair shedding 2\u20133 months after infection.<\/li>\n\n\n\n<li><strong>Duration<\/strong>: Typically resolves within 6 months, but may persist in long COVID.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Stress\u2011induced follicle cycling, cytokine surge, microvascular compromise.<\/li>\n\n\n\n<li><strong>Impact<\/strong>: Psychological distress, particularly in women and younger patients.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">5. Retiform Purpura and Livedo Reticularis<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Presentation<\/strong>: Net\u2011like bruising or purplish skin discoloration.<\/li>\n\n\n\n<li><strong>Duration<\/strong>: Associated with severe disease, but can persist in long COVID.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Thrombotic microangiopathy, complement activation.<\/li>\n\n\n\n<li><strong>Histology<\/strong>: Fibrin thrombi occluding dermal vessels.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">6. Exacerbation of Pre\u2011Existing Conditions<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eczema<\/strong>: Increased flares due to immune dysregulation.<\/li>\n\n\n\n<li><strong>Psoriasis<\/strong>: Worsening plaques linked to cytokine surge.<\/li>\n\n\n\n<li><strong>Alopecia areata<\/strong>: Autoimmune hair loss triggered or exacerbated by viral infection.<\/li>\n\n\n\n<li><strong>Seborrheic dermatitis<\/strong>: Stress and immune imbalance worsen symptoms.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Current Therapeutic Approaches<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">1. Symptomatic Management<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antihistamines<\/strong>: First\u2011line therapy for urticaria and angioedema. Both H1 and H2 blockers reduce histamine\u2011mediated itching and swelling.<\/li>\n\n\n\n<li><strong>Topical corticosteroids<\/strong>: Applied to papulosquamous eruptions, eczema flares, and chilblain\u2011like lesions to reduce inflammation.<\/li>\n\n\n\n<li><strong>Emollients and barrier creams<\/strong>: Support skin hydration and repair, especially in xerotic or eczematous conditions.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">2. Immunomodulators<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Systemic corticosteroids<\/strong>: Reserved for severe vasculitic or autoimmune rashes.<\/li>\n\n\n\n<li><strong>JAK inhibitors (e.g., baricitinib, ruxolitinib)<\/strong>: Target cytokine signaling pathways implicated in persistent inflammation.<\/li>\n\n\n\n<li><strong>Biologics<\/strong>: IL\u20116 inhibitors (tocilizumab), TNF\u2011\u03b1 blockers (adalimumab), and dupilumab (IL\u20114\/IL\u201113 blockade) are being explored for refractory cases.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">3. Anticoagulants and Vascular Therapies<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Low\u2011molecular\u2011weight heparin<\/strong>: Used in patients with retiform purpura or thrombotic vasculopathy.<\/li>\n\n\n\n<li><strong>Aspirin and antiplatelet agents<\/strong>: May reduce microvascular clotting and improve acral lesions.<\/li>\n\n\n\n<li><strong>Complement inhibitors<\/strong>: Experimental therapies targeting C5 (eculizumab) show promise in reducing vascular injury.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">4. Hair Loss Treatments<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Minoxidil (topical\/oral)<\/strong>: Stimulates follicle regrowth in telogen effluvium.<\/li>\n\n\n\n<li><strong>Nutritional support<\/strong>: Iron, vitamin D, and biotin supplementation may aid recovery.<\/li>\n\n\n\n<li><strong>Stress management<\/strong>: Psychological support reduces recurrence of stress\u2011induced shedding.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">5. Mast Cell Stabilizers<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ketotifen and cromolyn sodium<\/strong>: Reduce mast cell degranulation, alleviating chronic urticaria.<\/li>\n\n\n\n<li><strong>Omalizumab (anti\u2011IgE monoclonal antibody)<\/strong>: Effective in refractory long COVID urticaria.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Emerging and Experimental Therapies<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">1. IL\u20116 Blockade<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Tocilizumab and sarilumab, originally used in acute COVID cytokine storm, are being tested for persistent IL\u20116\u2011driven skin inflammation.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">2. Antiviral Strategies<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Persistent viral RNA in skin may respond to antivirals targeting replication.<\/li>\n\n\n\n<li>Ongoing trials are investigating remdesivir and molnupiravir in long COVID cohorts.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">3. Phototherapy<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Narrowband UVB phototherapy has shown benefit in psoriasis\u2011like eruptions.<\/li>\n\n\n\n<li>Potential role in modulating immune dysregulation in long COVID skin disease.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">4. Integrative Medicine<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Stress reduction techniques (mindfulness, yoga) improve neuroimmune signaling.<\/li>\n\n\n\n<li>Dietary interventions (anti\u2011inflammatory diets) may reduce systemic cytokine load.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Prognosis<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">1. COVID Toes<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Typically self\u2011limited, resolving within weeks to months.<\/li>\n\n\n\n<li>In long COVID, lesions may persist but rarely cause permanent damage.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">2. Urticaria<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Chronic urticaria may last >6 months, requiring long\u2011term antihistamine or biologic therapy.<\/li>\n\n\n\n<li>Prognosis improves with mast cell stabilizers and omalizumab.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">3. Papulosquamous Eruptions<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Often resolve spontaneously, but recurrence is possible.<\/li>\n\n\n\n<li>Prognosis depends on immune regulation and comorbid autoimmune disease.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">4. Telogen Effluvium<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Usually resolves within 6 months, but persistent shedding may occur in long COVID.<\/li>\n\n\n\n<li>Prognosis is favorable with supportive care.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">5. Retiform Purpura<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Associated with severe systemic disease.<\/li>\n\n\n\n<li>Prognosis depends on vascular recovery and anticoagulant therapy.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">6. Exacerbation of Pre\u2011Existing Conditions<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Prognosis varies: psoriasis and eczema may require long\u2011term biologic therapy.<\/li>\n\n\n\n<li>Autoimmune alopecia may persist, requiring immunomodulation.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Future Directions<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">1. Registries and Big\u2011Data Dermatology<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global registries<\/strong> such as the AAD\/ILDS COVID\u201119 Dermatology Registry have already catalogued thousands of cases, but future iterations must integrate genomic, proteomic, and metabolomic data.<\/li>\n\n\n\n<li><strong>Machine learning models<\/strong> can stratify risk by correlating skin phenotypes with systemic outcomes, predicting which patients are most likely to develop persistent dermatological sequelae.<\/li>\n\n\n\n<li><strong>Longitudinal follow\u2011up<\/strong> is essential: skin lesions may resolve, recur, or evolve into autoimmune conditions years after infection.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">2. Genomic Stratification of Risk<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Polygenic risk scores<\/strong> could identify individuals predisposed to severe cutaneous manifestations.<\/li>\n\n\n\n<li><strong>HLA typing<\/strong> may guide personalized therapy, especially in autoimmune rashes.<\/li>\n\n\n\n<li><strong>Epigenetic profiling<\/strong> could reveal stress\u2011induced modifications that exacerbate telogen effluvium and eczema.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">3. Integration of Dermatology into Long COVID Care<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Dermatologists must be embedded in multidisciplinary long COVID clinics.<\/li>\n\n\n\n<li>Skin lesions often precede systemic deterioration, serving as early warning signs.<\/li>\n\n\n\n<li><strong>Teledermatology<\/strong> platforms can expand access, particularly in underserved regions.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">4. Therapeutic Innovation<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted biologics<\/strong>: IL\u20116, TNF\u2011\u03b1, and JAK inhibitors tailored to cutaneous inflammation.<\/li>\n\n\n\n<li><strong>Complement inhibitors<\/strong>: Address vascular injury underlying purpura and livedo reticularis.<\/li>\n\n\n\n<li><strong>Regenerative medicine<\/strong>: Stem cell therapies for hair follicle recovery in telogen effluvium.<\/li>\n\n\n\n<li><strong>Integrative approaches<\/strong>: Stress reduction, diet, and lifestyle interventions to modulate neuroimmune signaling.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">5. Public Health and Policy<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Recognition of dermatological sequelae in disability frameworks.<\/li>\n\n\n\n<li>Insurance coverage for long COVID dermatology care.<\/li>\n\n\n\n<li>Education campaigns to destigmatize visible skin conditions associated with long COVID.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Conclusion<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Long COVID represents a complex interplay of viral persistence, immune dysregulation, vascular injury, and genomic susceptibility. The skin, as the most visible organ, provides a unique lens into this pathology. From chilblain\u2011like lesions and urticaria to papulosquamous eruptions and telogen effluvium, dermatological manifestations are diverse, persistent, and often distressing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Their etiology spans viral RNA persistence in keratinocytes, mast cell activation, complement\u2011mediated vasculopathy, and stress\u2011induced neuroimmune signaling. Genomic polymorphisms in ACE2, TMPRSS2, HLA, and cytokine genes further shape individual risk. Pathological findings confirm microvascular injury, interface dermatitis, and mast cell dysregulation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Therapeutic strategies range from antihistamines and corticosteroids to biologics, anticoagulants, and mast cell stabilizers. Emerging therapies \u2014 IL\u20116 blockade, complement inhibition, phototherapy, and regenerative medicine \u2014 promise more targeted interventions. Prognosis varies: while telogen effluvium and COVID toes often resolve, chronic urticaria and autoimmune exacerbations may persist.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Future directions demand integration of dermatology into long COVID care, genomic stratification of risk, and expansion of registries with big\u2011data analytics. Ultimately, the study of skin in long COVID is not merely cosmetic; it is a window into systemic disease, a sentinel of immune dysregulation, and a pathway to therapeutic innovation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">References<\/h3>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li>Colmenero I, et al. SARS\u2011CoV\u20112 endothelial infection in chilblains. <em>Br J Dermatol<\/em>. 2020.<\/li>\n\n\n\n<li>Magro C, et al. Endothelial injury in COVID\u201119 skin lesions. <em>Lancet Infect Dis<\/em>. 2020.<\/li>\n\n\n\n<li>Chen G, et al. Cytokine storm in COVID\u201119. <em>J Clin Invest<\/em>. 2020.<\/li>\n\n\n\n<li>Damsky W, et al. Cutaneous manifestations of COVID\u201119. <em>JAMA Dermatol<\/em>. 2021.<\/li>\n\n\n\n<li>Weinstock LB, et al. Mast cell activation in long COVID. <em>Front Immunol<\/em>. 2021.<\/li>\n\n\n\n<li>Zhou Y, et al. Autoantibodies in COVID\u201119. <em>Nature<\/em>. 2021.<\/li>\n\n\n\n<li>Magro C, et al. Complement-mediated microvascular injury. <em>Transl Res<\/em>. 2020.<\/li>\n\n\n\n<li>Ackermann M, et al. Microvascular pathology in COVID\u201119. <em>NEJM<\/em>. 2020.<\/li>\n\n\n\n<li>Hubiche T, et al. Acral lesions in COVID\u201119. <em>J Eur Acad Dermatol Venereol<\/em>. 2020.<\/li>\n\n\n\n<li>Sungnak W, et al. ACE2 expression in keratinocytes. <em>Nat Med<\/em>. 2020.<\/li>\n\n\n\n<li>Novelli G, et al. HLA alleles and COVID susceptibility. <em>Front Immunol<\/em>. 2020.<\/li>\n\n\n\n<li>Pairo\u2011Castineira E, et al. Genetic mechanisms of severe COVID. <em>Nature<\/em>. 2021.<\/li>\n\n\n\n<li>Arck P, et al. Stress and skin immunity. <em>J Invest Dermatol<\/em>. 2006.<\/li>\n\n\n\n<li>Mieczkowska K, et al. Telogen effluvium after COVID\u201119. <em>JAAD Case Rep<\/em>. 2021.<\/li>\n\n\n\n<li>Physiology<\/li>\n\n\n\n<li>1. Cutaneous Vascular Physiology<\/li>\n\n\n\n<li>The skin is a highly vascular organ, with dermal capillaries supplying oxygen and nutrients to keratinocytes, fibroblasts, and hair follicles.<\/li>\n\n\n\n<li><strong>Microvascular injury<\/strong> in long COVID disrupts this balance, leading to hypoxia, ischemia, and inflammatory signaling.<\/li>\n\n\n\n<li><strong>Endothelial dysfunction<\/strong>: SARS\u2011CoV\u20112 infection induces endothelial apoptosis and loss of nitric oxide signaling, impairing vasodilation.<\/li>\n\n\n\n<li><strong>Complement activation<\/strong>: Deposition of C5b\u20119 complexes damages dermal vessels, producing purpura and livedo reticularis.<\/li>\n\n\n\n<li>2. Neuroimmune Signaling<\/li>\n\n\n\n<li>The skin is an immunological and neurological interface.<\/li>\n\n\n\n<li><strong>Mast cells<\/strong> release histamine, tryptase, and cytokines, driving urticaria and angioedema.<\/li>\n\n\n\n<li><strong>Neuropeptides<\/strong> such as substance P and calcitonin gene\u2011related peptide (CGRP) amplify pruritus and vasodilation.<\/li>\n\n\n\n<li><strong>Stress hormones<\/strong> (cortisol, catecholamines) modulate mast cell activity, linking psychological stress to dermatological flares.<\/li>\n\n\n\n<li>3. Hair Cycle Physiology<\/li>\n\n\n\n<li>Hair follicles cycle through anagen (growth), catagen (regression), and telogen (rest).<\/li>\n\n\n\n<li><strong>Telogen effluvium<\/strong> occurs when systemic stress or cytokine surges prematurely shift follicles into telogen.<\/li>\n\n\n\n<li><strong>Cytokine involvement<\/strong>: IL\u20111 and TNF\u2011\u03b1 inhibit keratinocyte proliferation, accelerating follicle regression.<\/li>\n\n\n\n<li><strong>Microvascular compromise<\/strong>: Reduced blood flow impairs follicle nutrition, worsening hair shedding.<\/li>\n\n\n\n<li>Clinical Manifestations<\/li>\n\n\n\n<li>1. COVID Toes (Chilblains\/Pernio)<\/li>\n\n\n\n<li><strong>Presentation<\/strong>: Painful, erythematous or violaceous lesions on toes and fingers, often with swelling.<\/li>\n\n\n\n<li><strong>Duration<\/strong>: Can persist for weeks to months in long COVID.<\/li>\n\n\n\n<li><strong>Pathophysiology<\/strong>: Interferon\u2011driven inflammation and microvascular injury.<\/li>\n\n\n\n<li><strong>Histology<\/strong>: Lymphocytic vasculitis, endothelial swelling, microthrombi.<\/li>\n\n\n\n<li>2. Urticaria and Angioedema<\/li>\n\n\n\n<li><strong>Presentation<\/strong>: Migratory, pruritic wheals; sometimes accompanied by swelling of lips or eyelids.<\/li>\n\n\n\n<li><strong>Duration<\/strong>: Chronic urticaria lasting >6 weeks has been reported in long COVID.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Mast cell activation, histamine release, and autoantibody formation.<\/li>\n\n\n\n<li><strong>Impact<\/strong>: Significant impairment of quality of life due to itching and sleep disturbance.<\/li>\n\n\n\n<li>3. Papulosquamous Eruptions<\/li>\n\n\n\n<li><strong>Presentation<\/strong>: Scaly papules and plaques resembling psoriasis or pityriasis rosea.<\/li>\n\n\n\n<li><strong>Duration<\/strong>: May last 20\u201370 days, sometimes recurring.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: T\u2011cell mediated keratinocyte injury, cytokine dysregulation.<\/li>\n\n\n\n<li><strong>Histology<\/strong>: Interface dermatitis, parakeratosis, basal cell vacuolization.<\/li>\n\n\n\n<li>4. Telogen Effluvium<\/li>\n\n\n\n<li><strong>Presentation<\/strong>: Diffuse hair shedding 2\u20133 months after infection.<\/li>\n\n\n\n<li><strong>Duration<\/strong>: Typically resolves within 6 months, but may persist in long COVID.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Stress\u2011induced follicle cycling, cytokine surge, microvascular compromise.<\/li>\n\n\n\n<li><strong>Impact<\/strong>: Psychological distress, particularly in women and younger patients.<\/li>\n\n\n\n<li>5. Retiform Purpura and Livedo Reticularis<\/li>\n\n\n\n<li><strong>Presentation<\/strong>: Net\u2011like bruising or purplish skin discoloration.<\/li>\n\n\n\n<li><strong>Duration<\/strong>: Associated with severe disease, but can persist in long COVID.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Thrombotic microangiopathy, complement activation.<\/li>\n\n\n\n<li><strong>Histology<\/strong>: Fibrin thrombi occluding dermal vessels.<\/li>\n\n\n\n<li>6. Exacerbation of Pre\u2011Existing Conditions<\/li>\n\n\n\n<li><strong>Eczema<\/strong>: Increased flares due to immune dysregulation.<\/li>\n\n\n\n<li><strong>Psoriasis<\/strong>: Worsening plaques linked to cytokine surge.<\/li>\n\n\n\n<li><strong>Alopecia areata<\/strong>: Autoimmune hair loss triggered or exacerbated by viral infection.<\/li>\n\n\n\n<li><strong>Seborrheic dermatitis<\/strong>: Stress and immune imbalance worsen symptoms.<\/li>\n\n\n\n<li>Representative References<\/li>\n\n\n\n<li>Freeman EE, et al. COVID\u201119 dermatology registry findings. <em>J Am Acad Dermatol<\/em>. 2020.<\/li>\n\n\n\n<li>Galv\u00e1n Casas C, et al. Classification of COVID\u201119 skin manifestations. <em>Br J Dermatol<\/em>. 2020.<\/li>\n\n\n\n<li>Damsky W, et al. Cutaneous manifestations of COVID\u201119. <em>JAMA Dermatol<\/em>. 2021.<\/li>\n\n\n\n<li>Magro C, et al. Microvascular injury in COVID\u201119 skin lesions. <em>Lancet Infect Dis<\/em>. 2020.<\/li>\n\n\n\n<li>Mieczkowska K, et al. Telogen effluvium after COVID\u201119. <em>JAAD Case Rep<\/em>. 2021.<\/li>\n\n\n\n<li>Weinstock LB, et al. Mast cell activation in long COVID. <em>Front Immunol<\/em>. 2021.<\/li>\n\n\n\n<li>Hubiche T, et al. Acral lesions in COVID\u201119. <em>J Eur Acad Dermatol Venereol<\/em>. 2020.<\/li>\n\n\n\n<li>Colmenero I, et al. SARS\u2011CoV\u20112 endothelial infection in chilblains. <em>Br J Dermatol<\/em>. 2020.<\/li>\n\n\n\n<li>Arck P, et al. Stress and skin immunity. <em>J Invest Dermatol<\/em>. 2006.<\/li>\n\n\n\n<li>Zhou Y, et al. Autoantibodies in COVID\u201119. <em>Nature<\/em>. 2021.<\/li>\n\n\n\n<li>Freeman EE, et al. COVID\u201119 dermatology registry findings. <em>J Am Acad Dermatol<\/em>. 2020.<\/li>\n\n\n\n<li>Galv\u00e1n Casas C, et al. Classification of COVID\u201119 skin manifestations. <em>Br J Dermatol<\/em>. 2020.<\/li>\n\n\n\n<li>Damsky W, et al. Cutaneous manifestations of COVID\u201119. <em>JAMA Dermatol<\/em>. 2021.<\/li>\n\n\n\n<li>Magro C, et al. Microvascular injury in COVID\u201119 skin lesions. <em>Lancet Infect Dis<\/em>. 2020.<\/li>\n\n\n\n<li>Mieczkowska K, et al. Telogen effluvium after COVID\u201119. <em>JAAD Case Rep<\/em>. 2021.<\/li>\n\n\n\n<li>Weinstock LB, et al. Mast cell activation in long COVID. <em>Front Immunol<\/em>. 2021.<\/li>\n\n\n\n<li>Zhou Y, et al. Autoantibodies in COVID\u201119. <em>Nature<\/em>. 2021.<\/li>\n\n\n\n<li>Arck P, et al. Stress and skin immunity. <em>J Invest Dermatol<\/em>. 2006.<\/li>\n\n\n\n<li>Novelli G, et al. HLA alleles and COVID susceptibility. <em>Front Immunol<\/em>. 2020.<\/li>\n\n\n\n<li>Pairo\u2011Castineira E, et al. Genetic mechanisms of severe COVID. <em>Nature<\/em>. 2021.<\/li>\n\n\n\n<li>Freeman EE, et al. COVID\u201119 dermatology registry findings. <em>J Am Acad Dermatol<\/em>. 2020.<\/li>\n\n\n\n<li>Galv\u00e1n Casas C, et al. Classification of COVID\u201119 skin manifestations. <em>Br J Dermatol<\/em>. 2020.<\/li>\n\n\n\n<li>Damsky W, et al. Cutaneous manifestations of COVID\u201119. <em>JAMA Dermatol<\/em>. 2021.<\/li>\n\n\n\n<li>Magro C, et al. Microvascular injury in COVID\u201119 skin lesions. <em>Lancet Infect Dis<\/em>. 2020.<\/li>\n\n\n\n<li>Zhou Y, et al. Autoantibodies in COVID\u201119. <em>Nature<\/em>. 2021.<\/li>\n\n\n\n<li>Pairo\u2011Castineira E, et al. Genetic mechanisms of severe COVID. <em>Nature<\/em>. 2021.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>John Murphy, CEO, The COVID-19 Long-haul Foundation Introduction The COVID\u201119 pandemic has left an indelible mark not only on global health systems but also on the human body in ways [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":14110,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[846,266,533],"tags":[],"class_list":["post-14099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-itch","category-itching","category-skin-dermatology"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14099"}],"version-history":[{"count":8,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14099\/revisions"}],"predecessor-version":[{"id":14109,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14099\/revisions\/14109"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/14110"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}